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Abstract Objective The aim of this study was to estimate
and compare the costs of vancomycin and teicoplanin in
the treatment of Gram-positive hospital infections in
Turkey using a cost minimisation analysis. Setting Hacettepe
University Hospital, Ankara, Turkey. Method The health-
care provider’s perspective was considered within formal
pharmacoeconomic assessment methodology. The records
of 76 patients who had been hospitalised and treated for
Gram-positive infections at Hacettepe University Hospital
between 16 July 2003 and 22 November 2003 were ret-
rospectively evaluated to obtain individual data on
resources and associated costs. Main outcome measure
From a cost minimisation perspective, hospital directors
may consider teicoplanin to be a relevant option in addition
to vancomycin. Result The estimated mean treatment cost
per patient was 1,780 TRY (1,101 EUR) for teicoplanin
and 1,429 TRY (884 EUR) for vancomycin, with statistical
analysis failing to reveal any significant difference between
the two drugs in terms of these total costs (p = 0.33). This
cost minimisation analysis shows that the average costs of
vancomycin and teicoplanin per patient observed did not
differ significantly. Conclusion Other potential advantages
of one drug over the other, as reported by other authors,
such as differing safety profiles or advantages in adminis-
tration, may ultimately decide which is preferred.
Keywords Cost minimisation analysis  Glycopeptide 
Pharmacoeconomics  Teicoplanin  Turkey  Vancomycin
Impact of findings on practice
• Prices and costs are fundamentally different concepts.
A cheaper drug can be a more costly alternative than an
expensive one.
• Decision makers should not only take the costs of drugs
into account when making treatment choices.
Introduction
Glycopeptide antibiotics have long been considered the
gold standard for the treatment of documented or suspected
life-threatening, multiresistant, Gram-positive bacterial
infections [1, 2]. Vancomycin is the sole glycopeptide
available in the USA, whereas teicoplanin is a widely
available alternative in Europe [3].
The aim of this study was to estimate and compare the
costs of vancomycin and teicoplanin for the treatment of
Gram-positive hospital infections using cost minimisation
analysis of data obtained in an observational setting from a
health-care provider’s perspective. Hospital data on
patients who received teicoplanin or vancomycin for the
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treatment of a Gram-positive bacterial infection in the
Internal Medicine Wards at Hacettepe University Hospital
(Ankara, Turkey) were used for this pharmacoeconomic
analysis. The cost minimisation framework is motivated by
assuming the equal effectiveness of the two drugs.
Background information on vancomycin vs teicoplanin
As assessed in clinical trials, teicoplanin and vancomycin
have similar clinical and bacteriological efficacy in the
treatment of Gram-positive infections [4]. Pharmacologi-
cally, these glycopeptide antibiotics have comparable
mechanisms of action on bacterial cell wall synthesis [5].
Yet vancomycin is poorly absorbed from the gastrointes-
tinal tract, and should therefore not be given to patients
orally. Moreover, intramuscular injection of vancomycin
causes considerable local pain, and is not recommended
[6, 7]. Vancomycin has a low therapeutic index, and a risk
of nephrotoxicity and ototoxicity that complicates the drug
therapy and necessitates strict therapeutic drug monitoring.
The most common method employed for the therapeutic
monitoring of vancomycin has been to measure peak and
trough levels at steady state and then individualise the dose
pharmacokinetically to achieve target levels [6, 8].
Anaphylactoid reaction to vancomycin (red-neck/
red-man syndrome) is the most common adverse effect [9].
In addition, chemical thrombophlebitis can occur in
patients with peripheral venous cannulas [10].
The advantages of the ease of administration and better
overall tolerance, particularly with respect to administra-
tion-related adverse effects and renal toxicity [1, 11], make
teicoplanin a valuable alternative to vancomycin [12, 13].
Furthermore, mainly as a result of a prolonged elimination
half-life, teicoplanin (approximately 47 h after therapeutic
serum concentration is reached) allows for once-daily
dosing [14]. If teicoplanin is used at a standard dosage
there is little indication to measure serum concentrations in
non-severe infections, with the exception of a few partic-
ular patient groups, such as those with burns or intravenous
drug users [15]. Dose-related nephrotoxicity, ototoxicity
and the red-neck (red-man) syndrome appear to be much
less of a problem than with vancomycin [4, 16].
Still, the acquisition costs of teicoplanin and vancomycin
vary from country to country; vancomycin drug acquisition
costs are generally less than those of teicoplanin because
vancomycin is available in a generic form. However, cost
minimisation studies conducted in Europe have demon-
strated that while the acquisition costs per dose of teicoplanin
were approximately twice those of vancomycin, the total
costs of a 2-week treatment with either agent were similar
[17, 18]. The objective of our current study was to reproduce
such findings based on the data of observational retrospective
patient files in an another local (Turkish) setting.
Patients and methods
The records of patients who received either teicoplanin or
vancomycin for the treatment of Gram-positive bacterial
infections while hospitalised in the Internal Medicine
Wards at Hacettepe University Hospital between 16 July
2003 and 22 November 2004 were reviewed retrospec-
tively. For data collection purposes, an original patient
record profile was made. In filling out these patient record
profiles, patient records, patient receipts, on-line discharge
cards concerning the hospitalisation dates and specific
forms were used. The latter were specifically directed at
monitoring vascular catheter infections and the empirical
therapies initiated in daily clinical practice. According to
the information obtained during expert meetings with cli-
nicians, we felt that we could validly assume that the
choice of either one of the drugs was not directly related to
patient characteristics that one would expect to highly
influence the costs (patient severity, age etc.).
Patients whose records could not be obtained, in par-
ticular, if patient profiles and hospital bills were not
available, were excluded from the study.
Pharmacoeconomic methodology
Vancomycin and teicoplanin were compared within a cost
minimisation framework, where the difference between
them is reduced to a comparison of costs. This cost mini-
misation design is justified by our plausible initial
assumption, postulating the equal efficacy of the two drugs.
The analysis was conducted from a health-care provider’s
perspective, in particular that of the Department of Internal
Medicine at Hacettepe University Hospital. The direct
medical costs taken into account were:
1. Drug costs: next to drug acquisition costs, the loading dose
of teicoplanin was explicitly included in the analysis.
2. Preparation and administration costs: the preparation
and administration costs taken into consideration for
both drugs were the specific infusion solution (for
example, 0.9% NaCl 100 ml PVC), the infusion
system and the syringes used. The cost of nursing
staff time was not included in the analysis. When
teicoplanin was administered intramuscularly only the
cost of the syringe was included.
3. Drug monitoring costs: unlike teicoplanin, vancomycin
requires serum level monitoring, and therefore the
laboratory test costs and the regular monitoring of
serum levels were included.
4. Costs of the treatment of adverse effects: in particular,
the costs of directly treating the adverse effect or of
prophylaxis (for example, pheniramine to prevent
allergic reactions) were taken into consideration.
Pharm World Sci (2008) 30:916–923 917
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5. Costs of treatment failure: in patients in whom
treatment was discontinued due to an adverse effect,
ineffectiveness of therapy or for any other reason, the
costs associated with the next alternative drug used
were attributed to the costs of the therapy with the
initial drug of choice.
The daily unit costs shown in Tables 1 and 2 were used
to calculate the treatment costs for each patient. The drug
price list valid from 9 September 2005 issued by the
General Directorate of Pharmacy and Pharmaceuticals was
used for calculating drug acquisition costs. Furthermore,
the costs of hospital days during glycopeptide therapy were
calculated using the Financial Year Budget Application
Directive for 2005.
Data evaluation
Study data were analysed using the SPSS (version 11.0;
SPSS, Chicago, IL, USA) statistical package and specific
routines in R (version 2.5.0; R, Vienna, Austria) were used
to fit probability distributions to data on length of stay and
costs [19]. Categorical data were compared using the Chi-
squared test or Fisher’s exact test when the frequencies
expected were very small, whereas the independent sample
t test was reserved for continuous data assuming normal
distributions [20]. However, normality does obviously not
always apply to continuous data; the distribution of costs
and health-care resources are often right-skewed. This
occurs due to low percentages of patients with relatively
extreme high costs (e.g. medical complications, prolonged
hospital stay or the occurrence of side effects). Therefore,
we explicitly modelled the distributional form of the costs
and the length of stay [21]. In particular, we fitted distri-
butions of the family of the generalised F distribution,
which comprises, for example, the log-normal distribution,
but is broader and thus allows more flexibility [22]. We
used the Akaike Information Criterion AIC = -2
9 (maximum log likelihood) ? 2 k, where k is the number
of model parameters as a goodness-of-fit measure. We took
into account the estimated parameters of the generalised F
distribution combined with the values of the AIC to make
inferences on the distribution that fits the data best. Sub-
sequently, a parametric regression model was used to
estimate the effect of the different treatment groups on the
outcomes (i.e. costs or length of stay). Finally, we used
the moments of the best fitted distribution to estimate the
expected value and the variance.
Results
A total of 79 patients were treated for Gram-positive hos-
pital infections. They were all treated with either
vancomycin or teicoplanin. Three patients were excluded
from the final analysis due to the lack of access to patient
profiles, hospital bills and hospital discharge cards.
Therefore, the number of patients included in this study
was 76.
Patients’ characteristics
Of the 76 patients, 43 (56.6%) were men and 33 (43.4%)
were women. No significant difference was observed when
patients in the vancomycin and teicoplanin groups were
compared in terms of gender (p = 0.936). The patients
were between 17 and 83 years of age, with a mean age of
48.72 ± 15.32 years. The median age was 50 for both the
vancomycin and teicoplanin groups (p = 0.903). Patients’
characteristics are summarised in Table 3.
Of the co-morbid diseases and conditions encountered
among patients, haematological malignancies were fore-
most at 47.1%, followed by solid tumours and neurological
disorders at 10.6% each. In terms of indications for treat-
ment, nearly half of the patients (48.7%) were given a




Trade name of drugs
Vancomycin (generic 1) 500 mg i.v. vial 11.87 7.34
Vancomycin (generic 2) 500 mg i.v. vial 11.60 7.18
Teicoplanin 400 mg i.v./i.m. vial 81.41 50.37
Pheniramine 2 ml 45.5 mg 5 ampule 0.51 0.32
Medical devices used during administration
Serum 0.9% NaCl 100 ml PVC 2.28 1.41
Intravenous infusion kite 0.57 0.35
Syringe/injector 0.20 0.12
Total administration cost per dose 3.05 1.89
Costs of drug monitoring
Unit cost of drug monitoring for vancomycin 21.19 13.11
a Indicative exchange rates announced at 15:30 on 27 January 2006
by the Central Bank of Turkey (1 EUR = 1.6163 TRY)
Table 2 Specific daily costs of hospital room types in Turkish liras
(TRY)a and Euros (EUR)
Room type Daily costs
TRY EUR
Sterile room 118.64 73.40
Intensive care unit 88.98 55.05
Standard-care rooma 8.31–26.69 5.14–16.51
a Exact costs vary depending on the specific class of the room
918 Pharm World Sci (2008) 30:916–923
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glycopeptide for the treatment of catheter-associated
infections, and 4 patients received treatment due to septi-
caemia. For both comorbidity (v2 = 5.706, p = 0.68) and
indications (v2 = 4.555, p = 0.473) no statistically signif-
icant differences were found between the two groups.
Clinical drug use
Teicoplanin was selected as first-line therapy in 43 patients
(57%), whereas 33 patients (43%) received vancomycin as
the initial drug of choice, 9 of whom were eventually
switched to teicoplanin. Only 2 patients who were initially
given teicoplanin were switched to vancomycin.
Local samples were taken from a total of 42 patients. Of
these patients, 18 received teicoplanin and 24 received
vancomycin as initial drug therapy. In 18 local samples
bacterial growth was observed. No statistically significant
difference was observed as a result of a Chi-squared test
between patients receiving teicoplanin and those receiving
vancomycin in terms of bacteria reproduction in their local
samples (v2 = 1.946, p = 0.163). Also, blood samples
were taken from a total of 48 patients. Of these patients, 26
received teicoplanin and 22 received vancomycin as first-
line drug therapy. In 15 blood samples bacterial growth
was observed. No significant difference was observed as a
result of a Chi-squared test between patients receiving
teicoplanin and those receiving vancomycin in terms of
bacteria reproduction in their blood samples (v2 = 1.031,
p = 0.310). The rest of the patients were given teicoplanin
or vancomycin as empirical therapy.
For all patients receiving vancomycin a standard dose of
1,000 mg twice daily was given. With teicoplanin, how-
ever, varying doses were employed, such as 400 mg once
daily for 17 patients (40%), 300 mg every 72 h for 1
patient, and 300 mg in every 48 h for 1 patient. In 2
patients, teicoplanin was given intramuscularly, while for
the remaining patients intravenous infusion was preferred.
A single loading dose was only applied in 13 patients out
of 43 who had received teicoplanin as first-line drug therapy
(30%). The loading dose was 800 mg for 5 patients and
700 mg for 3 patients. One patient each received either
1,000 mg, 950 mg, 840 mg, 720 mg or 600 mg. Similarly,
of the 9 patients who were switched to teicoplanin after
initially receiving vancomycin, 3 (33%) had received load-
ing doses, 600 mg in 2 patients and 1,000 mg in 1 patient.
Five of the patients who were given vancomycin as first-
line therapy underwent drug monitoring tests, once in 3
patients, twice in 1 patient and four tests in 1 patient.
Therefore, the total number of drug monitoring tests taken
into account calculating the costs was 9.
Table 3 Patients’
characteristics
a Totals add up to more than the
numbers of patients, as one
patient may suffer from more
than one baseline disease
Vancomycin (n = 33) Teicoplanin (n = 43) Total (n = 76)
Age
Average 48.97 ± 13.28 48.53 ± 16.87 48.72 ± 15.32
Range 18–72 17–83 17–83
Gender
Men/women 18/15 25/18 43/33
Baseline disease, n (%)
Haematological malignancy 15 (44.1) 25 (49.0) 40 (47.1)
Solid tumour 4 (11.8) 5 (9.8) 9 (10.6)
Kidney disease 1 (2.9) 1 (2.0) 2 (2.3)
Heart disease 2 (5.9) 3 (5.9) 5 (5.9)
Lung disease – 2 (3.9) 2 (2.4)
Diabetes mellitus 2 (5.9) 4 (7.8) 6 (7.1)
Collagen tissue diseases and vasculitides – 2 (3.9) 2 (2.4)
Neurological disorders 6 (17.7) 3 (5.9) 9 (10.6)
Other 4 (11.8) 6 (11.8) 10 (11.8)
Totala 34 (100) 51 (100) 85 (100)
Reason for treatment with a glycopeptide, n (%)
Catheter-associated infection 15 (45.5) 22 (51.2) 37 (48.7)
Abdominal infection 2 (6.1) 2 (4.7) 4 (5.3)
Skin and soft tissue infection 10 (30.3) 12 (27.9) 22 (29.0)
CNS infection 5 (15.2) 2 (4.7) 7 (9.2)
Lung infection – 2 (4.7) 2 (2.6)
Septicaemia 1 (3.0) 3 (7..0) 4 (5.3)
Total 33 (100) 43 (100) 76 (100)
Pharm World Sci (2008) 30:916–923 919
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A total of 9 adverse drug reactions (ADRs) developed in
8 of the 76 patients (10.5%) who had received vancomycin
and/or teicoplanin. The total number of ADRs encountered
during teicoplanin use is only 2 (clouded consciousness in 1
patient and an increase in the creatinine level plus tremor),
whereas of the 9 ADRs, 7 were due to vancomycin use (red-
neck/red-man syndrome, drug eruption, an increase in the
creatinine level ? tremor in only 1 patient each, and skin
eruption and increase in creatinine level in 4 patients).
Length of hospital stay
Overall, the patients’ length of hospital stay varied between
14 and 261 days. Patients’ days of hospitalisation during
their glycopeptide antibiotic therapy varied between 1 and
55 days. The distribution of the length of stay (on glyco-
peptide therapy) appeared to be clearly skewed to the right.
Based on the estimated parameters of the generalised F
distribution and the AIC, the log-normal and the general-
ised gamma distribution provided the best fit for the total
length of stay and the length of stay on glycopeptide
therapy respectively. The expected values and expected
standard deviations are given in Table 4, which are the best
estimates of the mean population and standard deviation.
Using a parametric regression, no significant differences
were found between the vancomycin and teicoplanin
groups with regard to the total length of stay (p = 0.93)
and the number of days spent in hospital on glycopeptide
therapy (p = 0.15) respectively.
Costs
The results of statistical analyses comparing the total costs
of vancomycin and teicoplanin when given as first-line
drug therapy are summarised in Table 5. All the sample
distributions of the different cost components are clearly
right-skewed except for the distributions of the ADR costs
and the monitoring costs. For the right-skewed data the log-
normal or generalised gamma distribution provided the
best fit based on the estimated parameters of the general-
ised F distribution and the AIC. As there were only 5
patients who generated monitoring costs and 2 patients
who generated ADR costs, no formal statistical analyses
were performed on those data. Figure 1 shows the histo-
gram, and the fitted generalised gamma distribution, of the
total costs for both groups. We note that the sum of the
expected values of the separate cost categories does not
fully correspond to the expected value of the total costs.
Although the parametric distributions fit the data well, the
discrepancies are due to the fact that the log-normal or
generalised gamma distributions do not fit the data 100%.
The acquisition cost of teicoplanin was found to be
considerably higher than that of vancomycin (p \ 0.05),
while on the other hand, the administration costs of van-
comycin were higher than those of teicoplanin (p \ 0.001).
Furthermore, the difference between the total costs was not
statistically significant (p = 0.33). Besides, the estimated
mean treatment cost per patient was 1,780 TRY (1,101
EUR) for teicoplanin and 1,429 TRY (884 EUR) for van-
comycin, with statistical analysis failing to reveal any
significant difference between the two drugs in terms of
these total costs (p = 0.33).
Discussion
The selection of the specific evaluation method for phar-
macoeconomic analyses depends on the nature of outcomes
and the context in which the choices need to be made [23].
As in several articles it is indicated that both vancomycin
and teicoplanin have comparable effectiveness [4, 24, 25],
we performed a cost minimisation analysis.
The retrospective nature of our study did not allow for
any intervention in the physicians’ preference for drugs and
therapy duration. However, the fact that 43 of the 76
patients included in the study received teicoplanin as the
first-choice drug suggests a preference of physicians for
teicoplanin over vancomycin.
The dosages of vancomycin/teicoplanin administered
were similar to those suggested in the literature [14, 26,
27], according to which more ADRs are encountered dur-
ing the use of vancomycin. In a meta-analysis conducted
by Wood, it was emphasised that teicoplanin was tolerated
better than vancomycin in terms of ADRs and nephrotox-
icity [4]. Furthermore, in a study carried out by Codina
et al. [28], it was found that ADRs due to vancomycin use
(20.4%) were more frequent than those encountered with
teicoplanin use (1.6%). Finally, we note that in contrast to
Table 4 Length of hospital stay for patients receiving glycopeptides
First-line drug therapy p
Teicoplanin Vancomycin
Total length of staya
EV ± SD 75.54 ± 59.33 68.34 ± 40.90 0.93
Range 14–249 22–261 –
Median 59 62 –
Length of stay on glycopeptide therapyb
EV ± SD 12.75 ± 9.42 15.43 ± 15.97 0.15
Range 2–37 1–55 –
Median 13 13 –
SD = standard deviation; EV = expected value, based on the best
fitting distribution
a Log-normal distribution fitted best
b Gamma distribution fitted best
920 Pharm World Sci (2008) 30:916–923
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vancomycin use, the red-neck (red-man) syndrome is not a
significant problem during teicoplanin use [29]. In our
study it was observed that more ADRs occurred when
vancomycin was selected and used in the patients. How-
ever, due to the low number of patients and ADRs in this
study, it may be misleading to draw certain conclusions.
The ADRs mentioned could be investigated in more detail
in a larger patient group.
The average total therapy costs per patient were esti-
mated at 1,780 TRY (1,101 EUR) and 1,429 TRY (884
EUR) for patients who received teicoplanin and vanco-
mycin as first-choice therapy respectively. This difference
was not statistically significant. Although the acquisition
costs of vancomycin were significantly lower than those of
teicoplanin, the administration costs of vancomycin were
significantly higher (p \ 0.001). For patients who received
vancomycin as first-line therapy, the drug administration
costs contributed 13% to the total therapy cost. This rate
was 3% in patients who were given teicoplanin. Further-
more, teicoplanin as first-line therapy does not require the
monitoring of serum levels of the drug. Our finding is also
supported by another study carried out by Simoens et al. If
vancomycin was preferred in the treatment of catheter-
related infections, higher costs of laboratory tests as a
result of more frequent monitoring of serum concentrations
occurred [30].
Table 5 Total costs of first-line glycopeptide therapy (vancomycin or teicoplanin)
Costs Therapy p
Teicoplanin (n = 43) Vancomycin (n = 33)
Expected value SD Expected value SD
TRY EUR TRY TRY EUR TRY
Acquisition costsa 1,138.24 704.23 1,149.197 819.77 507.19 1,009.34 \0.05
Administration costsa 51.55 31.90 57.89 187.31 115.89 112.47 \0.001
Monitoring costs 0.00 0.00 0.00 5.78 3.58 16.98 *
ADR costs 0.00 0.00 0.00 1.07 0.66 4.94 *
Hospitalisation costsb 367.70 227.49 463.08 431.67 267.07 670.50 0.93
Total costsa 1,780.28 1,101.45 1,259.853 1,429.23 884.26 1,362.97 0.33
*Excluded from statistical analyses, numbers for monitoring costs are averages taken from the sample data, whereas elsewhere, expected values
from fitted distributions are shown
a Gamma distribution fitted best
b Log-normal distribution fitted best
Fig. 1 Total costs observed and the fitted generalised gamma distributions
Pharm World Sci (2008) 30:916–923 921
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Previously conducted European pharmacoeconomic
analyses have already demonstrated that 2-week courses of
either glycopeptide (teicoplanin or vancomycin) have
similar overall costs, when acquisition, preparation,
administration, and monitoring costs are included [17].
A retrospective cost analysis study conducted by Bucaneve
et al. showed that despite the higher acquisition cost of
teicoplanin in comparison to vancomycin, the lower inci-
dence of adverse effects associated with teicoplanin and its
ease of administration (a single daily dose) resulted in
equivalent overall treatment costs of teicoplanin and van-
comycin-containing regimens [31]. Vazquez et al. [24]
demonstrated that teicoplanin and vancomycin could be
administered in neutropenic haematologic patients even-
tuating in similar efficacy and direct costs. Furthermore,
Menichetti compared the clinical and microbiological
efficacy, cost per patient and tolerability of teicoplanin and
vancomycin as empirical or second-line treatment for
febrile neutropenic episodes in patients with haematologi-
cal or solid malignancies. While in terms of efficacy and
cost teicoplanin and vancomycin were found to be equiv-
alent, teicoplanin was better tolerated and could be used
effectively for out-patient treatment [25].
In contrast, a cost minimisation analysis study con-
ducted by Abad et al. suggested that vancomycin was more
efficient than teicoplanin for the treatment of infections
caused by Gram-positive organisms in patients in Intensive
Care Units, since the efficacy and the safety of vancomycin
and teicoplanin seemed similar and the global treatment
costs for vancomycin were lower [32]. In the prospective
cost analysis study conducted by Davey et al. the mean
daily costs were estimated at £52.40 (approximately 65.38
EUR) for teicoplanin and £31.13 (approximately 38.84
EUR) for vancomycin. Use of a loading dose of teicoplanin
significantly increased the mean daily drug costs if the
duration of treatment was less than 10 days. However,
administration of teicoplanin via the intramuscular route
would reduce the costs because i.v. cannulae would not be
required [33]. Likewise, in a recent cost minimisation
analysis conducted with a Delphi survey technique, the
mean treatment costs amounted to 1,272 EUR with tei-
coplanin and 1,041 EUR with vancomycin. The findings
do, however, indicate that the physicians administer higher
loading doses of teicoplanin than recommended in the drug
information leaflet [30].
A study assessing the economic impact of vancomycin
use versus teicoplanin use as antibiotic prophylaxis for
patients undergoing surgery for valve replacement and
coronary artery by-pass procedures conducted by Codina
et al. indicated that teicoplanin is the preferred option if the
drug is administered in surgical wards, while vancomycin
is the least costly option when administered in medical
wards [28].
The outcomes of pharmacoeconomic evaluations may
vary due to the specific design of each individual study
and/or the perspective selected. However, we note that the
results obtained in this study were generally comparable to
those of most other country-specific studies that compared
these glycopeptide antibiotics, i.e. the costs of vancomycin
and teicoplanin treatment do not significantly differ in a
situation where equal effectiveness is assumed. If this is the
case, other potential advantages of teicoplanin over van-
comycin as reported by others [1, 4, 11–13, 16, 28, 29],
such as differing safety profiles or advantages in adminis-
tration, may ultimately decide which should be preferred.
Our retrospective approach should be considered with
caution. Some bias may have been introduced, for example,
if physicians considered the clinical information of the
patient in the decision whether to choose one drug or the
other. Further research should be directed towards pro-
spectively designing this type of investigation and ideally
randomised settings should be chosen.
Conclusion
This cost minimisation analysis shows that the average
costs per patient observed did not differ significantly
whether vancomycin or teicoplanin was used. However,
from a cost minimisation perspective, hospital directors
may consider teicoplanin to be a relevant option in addition
to vancomycin. Other potential advantages of teicoplanin
over vancomycin as reported by others, such as differing
safety profiles or advantages in administration, may ulti-
mately decide which should be preferred. On the other
hand, though, it seems that it is essential for decision-
makers to estimate their own likely direct costs when
making a decision on which antibiotic therapy to choose.
By taking into consideration a number of similar studies
that have been conducted in various settings, and the level
of evidence of the relative contributions of acquisition and/
or monitoring costs in relation to these two antibiotics,
there is a need for a large and prospective randomised trial.
Funding No funding was received for this study.
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